These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6231426)

  • 1. The effects of Depo-Provera on serum protein levels in Nigerian women.
    Fajumi JO
    J Steroid Biochem; 1984 Feb; 20(2):581-3. PubMed ID: 6231426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic study of different doses of Depo Provera.
    Fotherby K; Koetsawang S; Mathrubutham M
    Contraception; 1980 Nov; 22(5):527-36. PubMed ID: 6451351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum immunoglobulin levels during contraceptive use of depot-medroxyprogesterone acetate in Indian women: a preliminary study.
    Lali P; Chandra L; Gupta RP
    Contraception; 1996 Jun; 53(6):363-5. PubMed ID: 8773424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo-Provera) as a contraceptive agent.
    Jeppsson S; Gershagen S; Johansson ED; Rannevik G
    Acta Endocrinol (Copenh); 1982 Mar; 99(3):339-43. PubMed ID: 6461995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in blood lipids and side effects induced by depo-provera in Nigerian women.
    Fajumi JO
    Contraception; 1983 Feb; 27(2):161-75. PubMed ID: 6221882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depo Provera: still controversial.
    Wren LM
    Int Health News; 1988 Feb; 9(2):2-3, 8. PubMed ID: 12179873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus.
    Petta CA; Faundes A; Dunson TR; Ramos M; DeLucio M; Faundes D; Bahamondes L
    Fertil Steril; 1998 Feb; 69(2):252-7. PubMed ID: 9496338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depo-Provera--ethical issues in its testing and distribution.
    Potts M; Paxman JM
    J Med Ethics; 1984 Mar; 10(1):9-20. PubMed ID: 6231379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
    Pardthaisong T; Gray RH; McDaniel EB
    Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case for concern?
    Gartland A
    Nurs Times; 1983 May 4-10; 79(18):10-1. PubMed ID: 6222288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug regulation in the United States and the United Kingdom: the Depo-Provera story.
    Richard BW; Lasagna L
    Ann Intern Med; 1987 Jun; 106(6):886-91. PubMed ID: 2953290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of Depo-Provera on carbohydrate and lipid metabolism.
    Liew DF; Ng CS; Yong YM; Ratnam SS
    Contraception; 1985 Jan; 31(1):51-64. PubMed ID: 3157546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Forearm bone density in users of Depo-Provera as a contraceptive method.
    Bahamondes L; Perrotti M; Castro S; Faúndes D; Petta C; Bedone A
    Fertil Steril; 1999 May; 71(5):849-52. PubMed ID: 10231044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives.
    Cromer BA; Blair JM; Mahan JD; Zibners L; Naumovski Z
    J Pediatr; 1996 Nov; 129(5):671-6. PubMed ID: 8917232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women.
    Fahmy K; Khairy M; Allam G; Gobran F; Alloush M
    Contraception; 1991 Oct; 44(4):431-44. PubMed ID: 1836755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate.
    Fotherby K; Saxena BN; Shrimanker K; Hingorani V; Takker D; Diczfalusy E; Landgren BM
    Fertil Steril; 1980 Aug; 34(2):131-9. PubMed ID: 7409232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medroxyprogesterone acetate in human serum.
    Mathrubutham M; Fotherby K
    J Steroid Biochem; 1981 Aug; 14(8):783-6. PubMed ID: 6457936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
    Petta CA; Faúndes A; Dunson TR; Ramos M; DeLucio M; Faúndes D; Bahamondes L
    Fertil Steril; 1998 Nov; 70(5):817-20. PubMed ID: 9806559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels of medroxyprogesterone acetate (MPA), estradiol and progesterone in the rhesus monkey after intramuscular adminstration of Depo-Provera.
    Mora G; Johansson ED
    Contraception; 1976 Sep; 14(3):343-50. PubMed ID: 824097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depo-Provera use in an Australian metropolitan practice.
    Fraser IS; Dennerstein GJ
    Med J Aust; 1994 May; 160(9):553-6. PubMed ID: 8164553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.